Viatris is trading at $18.17, up 4.16%, with the gain appearing aligned with a defensive rotation into healthcare.
- XLV was up 2.12% during the regular session.
- Market coverage also described Viatris as benefiting from that rotation, while technology stocks faced pressure from inflation and rate concerns.
- No clear company-specific announcement was found on October 15; the previously announced Pacira deal and analyst commentary are background, not confirmed direct causes of the session’s gain.